Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$60.36
+3.1%
$61.34
$43.70
$86.53
$1.92B-1.4447,081 shs25,190 shs
Indivior PLC stock logo
INDV
Indivior
$13.90
+0.9%
$11.57
$7.33
$16.98
$1.92B0.661.11 million shs800,478 shs
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
$26.04
-0.3%
$10.38
$8.94
$11.70
$480.53M0.08102,067 shs3,745 shs
Select Medical Holdings Corporation stock logo
SEM
Select Medical
$14.94
+1.4%
$15.59
$14.03
$40.98
$1.92B1.34965,455 shs1.68 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.00%-2.86%-6.87%-10.29%+21.57%
Indivior PLC stock logo
INDV
Indivior
0.00%-0.22%+21.50%+41.55%-12.36%
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
-0.30%-0.52%-0.18%+1,422.77%+4,860.83%
Select Medical Holdings Corporation stock logo
SEM
Select Medical
0.00%-1.86%-1.14%-9.76%-56.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.887 of 5 stars
3.53.00.00.04.00.80.6
Indivior PLC stock logo
INDV
Indivior
1.9426 of 5 stars
1.65.00.00.01.11.71.9
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/AN/AN/AN/AN/AN/AN/AN/A
Select Medical Holdings Corporation stock logo
SEM
Select Medical
4.9985 of 5 stars
3.43.02.54.82.44.25.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
3.00
Buy$96.6760.15% Upside
Indivior PLC stock logo
INDV
Indivior
3.25
Buy$15.007.91% Upside
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
0.00
N/AN/AN/A
Select Medical Holdings Corporation stock logo
SEM
Select Medical
2.80
Moderate Buy$26.0074.06% Upside

Current Analyst Ratings Breakdown

Latest LCAP, SEM, INDV, and BLTE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/15/2025
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
5/7/2025
Select Medical Holdings Corporation stock logo
SEM
Select Medical
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$23.00 ➝ $19.00
4/16/2025
Select Medical Holdings Corporation stock logo
SEM
Select Medical
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$25.00
3/26/2025
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$4.72 per shareN/A
Indivior PLC stock logo
INDV
Indivior
$1.19BN/A$1.82 per share7.64($2.52) per shareN/A
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/AN/A$1.26 per share20.64($2.85) per shareN/A
Select Medical Holdings Corporation stock logo
SEM
Select Medical
$5.22B0.37$2.51 per share5.96$15.35 per share0.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$36.14M-$1.36N/AN/AN/AN/A-32.07%-30.91%8/8/2025 (Estimated)
Indivior PLC stock logo
INDV
Indivior
$2M-$0.31N/A8.13N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
$3.21MN/A0.00N/AN/A-44.30%1.39%N/A
Select Medical Holdings Corporation stock logo
SEM
Select Medical
$214.04M$1.3411.1510.590.792.81%11.04%3.25%7/30/2025 (Estimated)

Latest LCAP, SEM, INDV, and BLTE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Select Medical Holdings Corporation stock logo
SEM
Select Medical
$0.45$0.44-$0.01$0.44$1.40 billion$1.35 billion
4/24/2025Q1 2025
Indivior PLC stock logo
INDV
Indivior
$0.22$0.41+$0.19$0.38$240.13 million$266.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/AN/AN/AN/AN/A
Select Medical Holdings Corporation stock logo
SEM
Select Medical
$0.251.67%N/A18.66%N/A

Latest LCAP, SEM, INDV, and BLTE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/1/2025
Select Medical Holdings Corporation stock logo
SEM
Select Medical
quarterly$0.06251.37%5/15/20255/15/20255/29/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
24.31
24.31
Indivior PLC stock logo
INDV
Indivior
N/A
0.88
0.72
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/A
0.05
0.05
Select Medical Holdings Corporation stock logo
SEM
Select Medical
0.87
1.16
1.16

Institutional Ownership

CompanyInstitutional Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
Indivior PLC stock logo
INDV
Indivior
60.33%
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/A
Select Medical Holdings Corporation stock logo
SEM
Select Medical
89.48%

Insider Ownership

CompanyInsider Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
13.29%
Indivior PLC stock logo
INDV
Indivior
N/A
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
19.40%
Select Medical Holdings Corporation stock logo
SEM
Select Medical
11.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
1031.84 million27.61 millionNot Optionable
Indivior PLC stock logo
INDV
Indivior
1,051N/AN/ANot Optionable
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
318.45 million14.87 millionNot Optionable
Select Medical Holdings Corporation stock logo
SEM
Select Medical
44,100128.54 million113.63 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$60.36 +1.81 (+3.09%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$59.90 -0.46 (-0.77%)
As of 06/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Indivior stock logo

Indivior NASDAQ:INDV

$13.90 +0.13 (+0.94%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$13.91 +0.01 (+0.07%)
As of 06/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Lionheart Acquisition Co. II stock logo

Lionheart Acquisition Co. II NASDAQ:LCAP

Lionheart Acquisition Corporation II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in PropTech sector. The company was incorporated in 2019 and is based in Miami, Florida.

Select Medical stock logo

Select Medical NYSE:SEM

$14.94 +0.21 (+1.41%)
Closing price 06/18/2025 03:59 PM Eastern
Extended Trading
$14.94 +0.00 (+0.02%)
As of 06/18/2025 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Select Medical Holdings Corporation, through its subsidiaries, operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. It operates in four segments: Critical Illness Recovery Hospital, Rehabilitation Hospital, Outpatient Rehabilitation, and Concentra. The Critical Illness Recovery Hospital segment consists of hospitals that provide services for heart failure, infectious disease, respiratory failure and pulmonary disease, surgery requiring prolonged recovery, renal disease, neurological events, and trauma. The Rehabilitation Hospital segment offers therapy and rehabilitation treatments, including rehabilitative services for brain and spinal cord injuries, strokes, amputations, neurological disorders, orthopedic conditions, pediatric congenital or acquired disabilities, and cancer. The Outpatient Rehabilitation segment operates rehabilitation clinics that provide physical, occupational, and speech rehabilitation programs and services; and specialized programs, such as functional programs for work related injuries, hand therapy, post-concussion rehabilitation, pediatric and cancer rehabilitation, and athletic training services. The Concentra segment operates and provides occupational health centers, telemedicine platforms, onsite clinics, and contract services at employer worksites that deliver occupational health services, consumer health, physical therapy, and preventive care. Select Medical Holdings Corporation was founded in 1996 and is headquartered in Mechanicsburg, Pennsylvania.